CANSLIM & Growth
Nuclear Growth (2x Revenue and Profit in 2 Years) is a CANSLIM & Growth screen. It checks every NSE-listed stock against 2 conditions computed from nightly data, after excluding heavily pledged promoters and very small market caps. This page explains the rule, each figure and its source. It lists no stocks and is not advice.
Most long-term compounding screens — Coffee Can's 8-year CAGR, Multibagger's 5-year EPS threshold — are designed to find businesses that have demonstrated sustained excellence over a decade. They are inherently backward-looking over long horizons. This screener asks a different and more immediate question: which businesses are right now in the middle of an explosive growth phase? Doubling revenue AND profit in two fiscal years implies a compound annual growth rate above 41% — a rate that, if sustained for even two more years, transforms a small-cap into a mid-cap and a mid-cap into a large-cap. The two-year window is deliberately short and demanding: it eliminates recovery plays (which show strong growth off depressed bases over 4-5 years) and instead focuses on businesses where the underlying business model is scaling faster than the market has priced in. The joint requirement — revenue AND profit doubling — is the key differentiator from pure revenue screens. Revenue doubling without profit doubling indicates a business sacrificing economics to buy market share; the combination of both doubling confirms that growth is accompanied by maintained or improved unit economics.
A stock must satisfy every condition below. Conditions are grouped under the pillar they test.
Revenue Explosion
Profit Explosion
Hard excludes
Ranked by PAT Growth (2Y), highest first.
Revenue 2-Year Growth %
(revenue_latest_annual - revenue_2yr_prior_annual) / revenue_2yr_prior_annual * 100. Revenue sourced from FinEdge annual income statement (statement_code=pl, period=annual). A value of 100% means revenue exactly doubled; the screener pass threshold is >100%.
The primary revenue doubling signal. Growth of >100% in two fiscal years is achieved by a tiny fraction of listed companies in any given year — typically 2-5% of the NSE universe. Companies appearing here are almost certainly gaining market share aggressively, entering a new market, or experiencing a structural demand surge in their core business. Analyst investigation should identify which of these is driving the growth before position-sizing decisions.
High is better
PAT 2-Year Growth %
(profitOrLossAttributableToOwners_latest_annual - profitOrLossAttributableToOwners_2yr_prior_annual) / abs(profitOrLossAttributableToOwners_2yr_prior_annual) * 100. Uses absolute denominator to handle edge case where the base year PAT was a small positive. Computed only when the base year PAT is positive; flagged as not computable when the base year showed a loss (loss-to-profit turnarounds should be evaluated separately).
High is better
Revenue CAGR 2-Year %
(revenue_latest_annual / revenue_2yr_prior_annual) ^ (1/2) - 1, expressed as a percentage. CAGR form of the 2-year revenue doubling. A doubling implies approximately 41.4% CAGR. Displayed alongside the raw growth percentage to allow comparison with other screeners that use CAGR notation.
High is better
Type hypothetical values to see which conditions they satisfy. These are not real stocks and nothing here is stored.
Enter values to begin
How many stocks pass if this threshold were set differently. Counts only; no stocks are named.
Loading the worked example…
Sign in with a completed risk profile to check any stock against this rule.
We have not measured this screen yet, so there is no record to explain.
Not yet testable — 5 of 6 points needed to chart a rolling information coefficient.
This is a historical, statistical measurement produced by FINOME TECHNOLOGIES PVT LTD's research harness on past data. It is not a prediction, and past results do not indicate future results. The universe is today's Nifty 500 constituents, so the sample is affected by survivorship bias. It describes how a screen's selections behaved in the past and does not constitute investment advice or a recommendation.
Rule version 1.0.0